Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.
Clin Adv Hematol Oncol. 2023 May;21(5):247-256.
The treatment landscape for multiple myeloma (MM) has evolved significantly over the last decade with the approval of novel therapies and combinations in the newly diagnosed and relapsed/refractory settings. There has also been a shift toward a risk-adapted approach to induction and maintenance regimens, with the goal of achieving better response rates for those with high-risk disease. The incorporation of anti-CD38 monoclonal antibodies into induction regimens has led to longer progression-free survival and higher rates of measurable residual disease negativity. In the relapsed setting, the emergence of B-cell maturation antigen-directed therapy, including antibody-drug conjugates, chimeric antigen receptor T-cell therapy, and more recently, bispecific antibodies, has produced deep and durable responses in heavily pretreated patients. This review article describes novel approaches to the treatment of MM in both the newly diagnosed and the relapsed/refractory setting.
在过去的十年中，多发性骨髓瘤（MM）的治疗领域发生了重大变化，新诊断和复发/难治性疾病的新型治疗方法和联合治疗方案已获得批准。此外，诱导和维持治疗方案也朝着风险适应的方向转变，目标是为高危疾病患者实现更好的反应率。将抗 CD38 单克隆抗体纳入诱导治疗方案可导致无进展生存期延长和更高的可测量残留疾病阴性率。在复发环境中，B 细胞成熟抗原导向治疗的出现，包括抗体药物偶联物、嵌合抗原受体 T 细胞疗法，以及最近的双特异性抗体，为大量预处理患者产生了深度和持久的反应。这篇综述文章描述了新诊断和复发/难治性多发性骨髓瘤的治疗新方法。
